A novel investigational endoscopic procedure targeting the duodenum appears beneficial in improving glycemic parameters in ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Multiple factors have a generation of medical students and young physicians struggling with mental health like never before.

Short-interval CT imaging is a safe and cost-effective strategy for focal indeterminate consolidation in lung cancer ...

Living within a mile of a golf course is associated with a 126% increased risk for Parkinson’s disease possibly due to ...

Young men growing up with mothers physically abused by partners are more likely than young women to commit partner violence, ...

Learning your risk for Alzheimer’s disease through amyloid PET imaging does not appear to lead to emotional distress but may ...

After pain, nausea and vomiting are the most documented symptoms in patients with cancer preceding unplanned acute care ...

Non-invasive biomarkers and scoring systems show strong capability in differentiating chronic liver disease from cirrhosis, ...

Cataract surgery may not increase the risk for postoperative endophthalmitis or severe systemic adverse events in patients ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...